FDA-cleared profile

See-Mode Augmented Reporting Tool, Thyroid (SMART-T)

See-Mode Technologies Pte. Ltd. · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.

Clinical role
Stand-alone lesion localization, characterization, and structured-reporting aid; the clinician may modify the report during quality control and patient management must not rely solely on the software analysis.
Images and patients
Ultrasound · Thyroid
Key limitation
Keep in mind: The report requires qualified-clinician review, quality control, and approval; the software is not an independent source of medical advice and patient-management decisions must not be based solely on its analysis. Exact current interfaces, versions, and local compatibility are not established.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Thyroid Input: DICOM thyroid ultrasound images from DICOM-compliant ultrasound imaging devices for adults aged 22 years or older referred for examination.
  • Who uses it?Intended users: Trained medical professionals, including physicians and medical technicians such as radiologists; a qualified clinician reviews and approves the report.
  • What does the software produce?Output: Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.
  • What is its most important limitation?Key limitation: The report requires qualified-clinician review, quality control, and approval; the software is not an independent source of medical advice and patient-management decisions must not be based solely on its analysis. Exact current interfaces, versions, and local compatibility are not established.

Clinical takeaway. Clinical role: Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.

Evidence takeaway. Evidence from the reviewed source record: FDA performance testing included a standalone study and an MRMC reader study with 600 unique patients/cases and 18 board-certified radiologists. For localization at IoU greater than 0.5, average reader AUC was 0.758 aided, 0.736 unaided, and standalone AUC was 0.703 (95% CI 0.642-0.762). Reader localization accuracy was 95.6% aided, 93.6% unaided, and 95.1% standalone. Standalone descriptor accuracy was 86.7% composition, 68.2% echogenicity, 93.4% shape, 58.4% margin, and 70.3% echogenic foci; standalone overall TI-RADS-level agreement was 63.8% (95% CI 60.0-67.7). Ground truth used FNA or two-year follow-up for benign/malignant status and expert radiologist consensus with adjudication for localization and descriptors.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adult thyroid ultrasound reporting aid for localizing and characterizing suspicious nodules with ACR TI-RADS descriptors and categories.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Stand-alone lesion localization, characterization, and structured-reporting aid; the clinician may modify the report during quality control and patient management must not rely solely on the software analysis.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM thyroid ultrasound images from DICOM-compliant ultrasound imaging devices for adults aged 22 years or older referred for examination.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Adult patients aged 22 years or older referred for a thyroid ultrasound examination in a clinical ultrasound reporting workflow.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained medical professionals, including physicians and medical technicians such as radiologists; a qualified clinician reviews and approves the report.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The report requires qualified-clinician review, quality control, and approval; the software is not an independent source of medical advice and patient-management decisions must not be based solely on its analysis. Exact current interfaces, versions, and local compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA performance testing included a standalone study and an MRMC reader study with 600 unique patients/cases and 18 board-certified radiologists. For localization at IoU greater than 0.5, average reader AUC was 0.758 aided, 0.736 unaided, and standalone AUC was 0.703 (95% CI 0.642-0.762). Reader localization accuracy was 95.6% aided, 93.6% unaided, and 95.1% standalone. Standalone descriptor accuracy was 86.7% composition, 68.2% echogenicity, 93.4% shape, 58.4% margin, and 70.3% echogenic foci; standalone overall TI-RADS-level agreement was 63.8% (95% CI 60.0-67.7). Ground truth used FNA or two-year follow-up for benign/malignant status and expert radiologist consensus with adjudication for localization and descriptors.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA performance testing included a standalone study and an MRMC reader study with 600 unique patients/cases and 18 board-certified radiologists. For localization at IoU greater than 0.5, average reader AUC was 0.758 aided, 0.736 unaided, and standalone AUC was 0.703 (95% CI 0.642-0.762). Reader localization accuracy was 95.6% aided, 93.6% unaided, and 95.1% standalone. Standalone descriptor accuracy was 86.7% composition, 68.2% echogenicity, 93.4% shape, 58.4% margin, and 70.3% echogenic foci; standalone overall TI-RADS-level agreement was 63.8% (95% CI 60.0-67.7). Ground truth used FNA or two-year follow-up for benign/malignant status and expert radiologist consensus with adjudication for localization and descriptors.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

See-Mode Augmented Reporting Tool, Thyroid (SMART-T) regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240697
  • Samplen=600
  • IndependenceIndependence not established

K240697

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240697. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM thyroid ultrasound images from DICOM-compliant ultrasound imaging devices for adults aged 22 years or older referred for examination.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240697: See-Mode Augmented Reporting Tool, Thyroid (SMART-T)

  2. Routing

    Source context, not route validation: Web-based client-server software accessed through a browser on a standard off-the-shelf computer, with DICOM input from ultrasound devices and structured-report output; the FDA packet does not establish a specific PACS, RIS, EHR, or interface version.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240697: See-Mode Augmented Reporting Tool, Thyroid (SMART-T)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240697: See-Mode Augmented Reporting Tool, Thyroid (SMART-T)

  5. Viewer/worklist/report

    Unresolved route: Regions of interest placed on thyroid ultrasound images, ACR TI-RADS lexicon descriptors for composition, echogenicity, shape, margin, and echogenic foci, a calculated TR-1 through TR-5 category, and a structured report with measurement and annotation tools.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240697: See-Mode Augmented Reporting Tool, Thyroid (SMART-T)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Web-based client-server software accessed through a browser on a standard off-the-shelf computer, with DICOM input from ultrasound devices and structured-report output; the FDA packet does not establish a specific PACS, RIS, EHR, or interface version.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for See-Mode Augmented Reporting Tool, Thyroid (SMART-T); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240697
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Thyroid
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-09-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240697 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K240697: See-Mode Augmented Reporting Tool, Thyroid (SMART-T)

    U.S. Food and Drug Administration - Published 2024-09-09 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. See-Mode Augmented Reporting Tool, Thyroid (SMART-T) model card (K240697)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240697

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K240697 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K240036

PIUR tUS Infinity

PIUR Imaging GmbH

Authorized purpose: PIUR tUS Infinity supports a computer-aided thyroid ultrasound workflow that identifies thyroid lobes and margins, calculates volume, marks and quantifies nodules, and provides user-selected ACR TI-RADS parameters subject to user review and confirmation.

Modality
Ultrasound
Anatomy
Thyroid
Decision
2024-09-20
FDA-cleared K203502

MEDO-Thyroid

MEDO DX Pte. Ltd.

Authorized purpose: Views and quantifies thyroid ultrasound data with machine learning to aid thyroid-lobe analysis and identify, quantify, and document nodules in adults age 18 or older.

Modality
Ultrasound
Anatomy
Thyroid
Decision
2021-04-23
FDA-cleared K260667

Alturion Series Diagnostic Ultrasound System

Philips Ultrasound, LLC

Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.

Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Decision
2026-06-29
FDA-cleared K260190

ARTHUR

ROPCA ApS

Authorized purpose: Supervised automatic ultrasound image acquisition of hand and wrist joints in adults being investigated or monitored for musculoskeletal disease.

Modality
Ultrasound
Anatomy
Hand/Wrist
Decision
2026-06-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history